Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 20.38% is 391% above its 5-year average of 4.15%, near the high end of its 5-year range (-16.67%–20.38%).
As of the fiscal period ended Tuesday, June 30, 2026. 131.78% above its 12-month average of 8.79%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 20.38%.
RETURN ON EQUITY (ROE)
20.38%
RETURN ON EQUITY (ROE) AVG TTM
8.79%
RETURN ON EQUITY (ROE) AVG 3Y
6.69%
RETURN ON EQUITY (ROE) AVG 5Y
4.15%
RETURN ON EQUITY (ROE) AVG 10Y
4.53%
RETURN ON EQUITY (ROE) AVG 15Y
10.75%
RETURN ON EQUITY (ROE) AVG 20Y
11.00%
CURRENT VS TTM AVG
+131.78%
CURRENT VS 3Y AVG
+204.85%
CURRENT VS 5Y AVG
+391.37%
CURRENT VS 10Y AVG
+349.66%
CURRENT VS 15Y AVG
+89.59%
CURRENT VS 20Y AVG
+85.39%
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+148.52%
vs the sector median at left
Ligand Pharmaceuticals Incorporated
Market Cap
$5.95B
Return on Equity (ROE)
20.38%
TTM Avg
8.79%
3Y Avg
6.69%
5Y Avg
4.15%
Market Cap
$5.89B
Return on Equity (ROE)
-15.40%
TTM Avg
-48.41%
3Y Avg
-63.30%
5Y Avg
-53.67%
Market Cap
$5.87B
Return on Equity (ROE)
12.33%
TTM Avg
0.28%
3Y Avg
12.51%
5Y Avg
-14.51%
Market Cap
$5.79B
Return on Equity (ROE)
-39.33%
TTM Avg
-54.18%
3Y Avg
-65.89%
5Y Avg
-59.69%
Market Cap
$5.78B
Return on Equity (ROE)
-396.09%
TTM Avg
-131.69%
3Y Avg
-109.48%
5Y Avg
-82.27%
Market Cap
$6.23B
Return on Equity (ROE)
-94.50%
TTM Avg
-115.58%
3Y Avg
-102.12%
5Y Avg
-85.25%
Market Cap
$5.61B
Return on Equity (ROE)
-21.80%
TTM Avg
-16.70%
3Y Avg
-22.00%
5Y Avg
-23.98%
Market Cap
$5.53B
Return on Equity (ROE)
-1.93%
TTM Avg
-0.70%
3Y Avg
0.57%
5Y Avg
0.69%
Market Cap
$5.52B
Return on Equity (ROE)
-9.09%
TTM Avg
-8.34%
3Y Avg
-4.98%
5Y Avg
-4.98%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ligand Pharmaceuticals Incorporated (LGND) | $5.95B | 20.38% | 8.79% | 6.69% | 4.15% |
| GRAIL Inc. (GRAL)vs › | $5.89B | -15.40% | -48.41% | -63.30% | -53.67% |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.87B | 12.33% | 0.28% | 12.51% | -14.51% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.79B | -39.33% | -54.18% | -65.89% | -59.69% |
| Kodiak Sciences Inc. (KOD)vs › | $5.78B | -396.09% | -131.69% | -109.48% | -82.27% |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.23B | -94.50% | -115.58% | -102.12% | -85.25% |
| CG Oncology Inc. (CGON)vs › | $5.61B | -21.80% | -16.70% | -22.00% | -23.98% |
| RadNet, Inc. (RDNT)vs › | $5.53B | -1.93% | -0.70% | 0.57% | 0.69% |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.52B | -9.09% | -8.34% | -4.98% | -4.98% |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.48B | 476.51% | 2.59% | -115.75% | -71.67% |
ROE
20.4%
ROA
9.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 20.38% |
| 2026-03-31 | 15.40% |
| 2025-12-31 | 12.23% |
| 2025-09-30 | 5.11% |
| 2025-06-30 | -9.16% |
| 2025-03-31 | -16.67% |
| 2024-12-31 | -0.49% |
| 2024-09-30 | 5.38% |
| 2024-06-30 | 5.44% |
| 2024-03-31 | 11.95% |
| 2023-12-31 | 7.44% |
| 2023-09-30 | 2.47% |
| 2023-06-30 | 4.08% |
| 2023-03-31 | 3.71% |
| 2022-12-31 | -5.58% |
| 2022-09-30 | -2.61% |
| 2022-06-30 | -0.99% |
| 2022-03-31 | 2.98% |
| 2021-12-31 | 6.96% |
| 2021-09-30 | 8.41% |
| 2021-06-30 | 6.09% |
| 2021-03-31 | 5.26% |
| 2020-12-31 | -0.42% |
| 2020-09-30 | -2.31% |
| 2020-06-30 | -3.55% |
| 2020-03-31 | -9.24% |
| 2019-12-31 | 82.02% |
| 2019-09-30 | 69.86% |
| 2019-06-30 | 64.99% |
| 2019-03-31 | 70.78% |
| 2018-12-31 | 25.55% |
| 2018-09-30 | 25.56% |
| 2018-06-30 | 19.34% |
| 2018-03-31 | 10.61% |
| 2017-12-31 | 3.00% |
| 2017-09-30 | 3.87% |
| 2017-06-30 | 2.11% |
| 2017-03-31 | -0.79% |
| 2016-12-31 | -0.44% |
| 2016-09-30 | 2.11% |
| 2016-06-30 | 52.65% |
| 2016-03-31 | 60.11% |
| 2015-12-31 | 75.50% |
| 2015-09-30 | 78.90% |
| 2015-06-30 | 47.29% |
| 2015-03-31 | 30.39% |
| 2014-12-31 | 45.69% |
| 2014-09-30 | 15.41% |
| 2014-06-30 | 11.72% |
| 2014-03-31 | 18.50% |
| 2013-12-31 | 23.02% |
| 2013-09-30 | 23.68% |
| 2013-06-30 | 21.53% |
| 2013-03-31 | 0.32% |
| 2012-12-31 | -1.00% |
| 2012-09-30 | 19.66% |
| 2012-06-30 | 2.50% |
| 2012-03-31 | 9.43% |
| 2011-12-31 | 119.21% |
| 2011-09-30 | 393.24% |
| 2011-06-30 | 25.74% |
| 2011-03-31 | 39.97% |
| 2010-06-30 | 68.00% |
| 2010-03-31 | 19.63% |
| 2009-12-31 | -51.95% |
| 2008-06-30 | -16.70% |
| 2008-03-31 | 14.00% |
| 2007-12-31 | 967.50% |
| 2007-03-31 | 670.38% |
| 2006-12-31 | -116.05% |
| 2004-09-30 | -68.85% |
| 2004-06-30 | -67.71% |
| 2004-03-31 | -50.16% |
| 2003-12-31 | -52.96% |
| 2003-09-30 | -80.09% |
| 2003-06-30 | -170.35% |
